Selinexor in myelofibrosis treatment ΡΠΊΠ°ΡΠ°ΡΡ Π² Ρ ΠΎΡΠΎΡΠ΅ΠΌ ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅
Selinexor in myelofibrosis treatment
3 years ago
Speaker: Michael Deininger
Institution: University of Utah
Event: ASH 2021
Format: Interview
Subject: Myelofibrosis
Subject: Myeloproliferative Neoplasms
Field: Disease Biology
Field: Treatment
Medicines: Selinexor
Janus kinase inhibitor
JAK inhibitor
MPN
XPO1
efficacy
safety
nuclear-cytoplasmic transport
ΠΠ΅ ΡΠ΄Π°Π΅ΡΡΡ Π·Π°Π³ΡΡΠ·ΠΈΡΡ Youtube-ΠΏΠ»Π΅Π΅Ρ. ΠΡΠΎΠ²Π΅ΡΡΡΠ΅ Π±Π»ΠΎΠΊΠΈΡΠΎΠ²ΠΊΡ Youtube Π² Π²Π°ΡΠ΅ΠΉ ΡΠ΅ΡΠΈ.
ΠΠΎΠ²ΡΠΎΡΡΠ΅ΠΌ ΠΏΠΎΠΏΡΡΠΊΡ...
ΠΠΎΠ²ΡΠΎΡΡΠ΅ΠΌ ΠΏΠΎΠΏΡΡΠΊΡ...
Π‘ΠΊΠ°ΡΠ°ΡΡ Π²ΠΈΠ΄Π΅ΠΎ Ρ ΡΡΡΠ± ΠΏΠΎ ΡΡΡΠ»ΠΊΠ΅ ΠΈΠ»ΠΈ ΡΠΌΠΎΡΡΠ΅ΡΡ Π±Π΅Π· Π±Π»ΠΎΠΊΠΈΡΠΎΠ²ΠΎΠΊ Π½Π° ΡΠ°ΠΉΡΠ΅: Selinexor in myelofibrosis treatment Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ 4k
Π£ Π½Π°Ρ Π²Ρ ΠΌΠΎΠΆΠ΅ΡΠ΅ ΠΏΠΎΡΠΌΠΎΡΡΠ΅ΡΡ Π±Π΅ΡΠΏΠ»Π°ΡΠ½ΠΎ Selinexor in myelofibrosis treatment ΠΈΠ»ΠΈ ΡΠΊΠ°ΡΠ°ΡΡ Π² ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΌ Π΄ΠΎΡΡΡΠΏΠ½ΠΎΠΌ ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅, Π²ΠΈΠ΄Π΅ΠΎ ΠΊΠΎΡΠΎΡΠΎΠ΅ Π±ΡΠ»ΠΎ Π·Π°Π³ΡΡΠΆΠ΅Π½ΠΎ Π½Π° ΡΡΡΠ±. ΠΠ»Ρ Π·Π°Π³ΡΡΠ·ΠΊΠΈ Π²ΡΠ±Π΅ΡΠΈΡΠ΅ Π²Π°ΡΠΈΠ°Π½Ρ ΠΈΠ· ΡΠΎΡΠΌΡ Π½ΠΈΠΆΠ΅:
-
ΠΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΏΠΎ Π·Π°Π³ΡΡΠ·ΠΊΠ΅:
Π‘ΠΊΠ°ΡΠ°ΡΡ mp3 Ρ ΡΡΡΠ±Π° ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΠΌ ΡΠ°ΠΉΠ»ΠΎΠΌ. ΠΠ΅ΡΠΏΠ»Π°ΡΠ½ΡΠΉ ΡΠΈΠ½Π³ΡΠΎΠ½ Selinexor in myelofibrosis treatment Π² ΡΠΎΡΠΌΠ°ΡΠ΅ MP3:
ΠΡΠ»ΠΈ ΠΊΠ½ΠΎΠΏΠΊΠΈ ΡΠΊΠ°ΡΠΈΠ²Π°Π½ΠΈΡ Π½Π΅
Π·Π°Π³ΡΡΠ·ΠΈΠ»ΠΈΡΡ
ΠΠΠΠΠΠ’Π ΠΠΠΠ‘Π¬ ΠΈΠ»ΠΈ ΠΎΠ±Π½ΠΎΠ²ΠΈΡΠ΅ ΡΡΡΠ°Π½ΠΈΡΡ
ΠΡΠ»ΠΈ Π²ΠΎΠ·Π½ΠΈΠΊΠ°ΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ ΡΠΎ ΡΠΊΠ°ΡΠΈΠ²Π°Π½ΠΈΠ΅ΠΌ Π²ΠΈΠ΄Π΅ΠΎ, ΠΏΠΎΠΆΠ°Π»ΡΠΉΡΡΠ° Π½Π°ΠΏΠΈΡΠΈΡΠ΅ Π² ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΡ ΠΏΠΎ Π°Π΄ΡΠ΅ΡΡ Π²Π½ΠΈΠ·Ρ
ΡΡΡΠ°Π½ΠΈΡΡ.
Π‘ΠΏΠ°ΡΠΈΠ±ΠΎ Π·Π° ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΡΠ²ΠΈΡΠ° ClipSaver.ru
Selinexor in myelofibrosis treatment
Selinexor inhibits karyopherin protein exportin 1 (XPO1) activity and is currently approved for diffuse large B-cell lymphoma (DLBCL) and multiple myeloma. Michael Deininger, MD, PhD, University of Utah, Salt Lake City, UT, provides an overview of the rationale behind using selinexor in treating myelofibrosis. Currently, there are limited treatment options for myelofibrosis, especially in patients resistant to Janus kinase (JAK) inhibitors. Preliminary studies have indicated clinical efficacy and safety in patients with myelofibrosis. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Comments
